WUHAN, March 6 (Xinhua) — Some vaccines against the COVID-19 are expected to enter clinical trials by mid-April or even earlier, an official said Friday.
Chinese scientists are racing to carry out scientific and technological breakthroughs in epidemic prevention and control by adopting five technological approaches, Ding Xiangyang, deputy secretary-general of the State Council, said at a press briefing Friday in Wuhan, the epicenter of the novel coronavirus outbreak.
The country has adopted treatment methods that combine traditional Chinese medicine (TCM) and Western medicine to cure the COVID-19 and carried out clinical trials and studies on different types of patients including those with mild symptoms after screening more than 5,000 kinds of drugs. TCM treatment has yielded good outcomes, preventing patients with mild symptoms from becoming severely ill, said Ding.
He added that, as of March 3, a total of 14 types of nucleic acid test reagents had been been made available through emergency approval.
- Indonesia's third Covid-19 wave expected to peak in mid-February
- Younger kids could be getting a Covid-19 vaccine within weeks. Here's what happens next
- Study links Covid-19 vaccination to small increase in menstrual cycle length, but experts say it's no cause for concern
- Covid-19 vaccines save lives; busting the anti-vaccination myths
- Corbevax: What Do We Know About Biological E's New COVID-19 Vaccine?
- The Covid-19 Vaccine Is Safe for Pregnant People, But Many Are Still Hesitant to Get the Jab
- Widening the safety net: On rollout of COVID-19 vaccines for health-care workers
- Paracetamol after Covid-19 vaccine: Only if doctor advises it
- Doctor argues for more research into effects of Covid-19 vaccines on menstruation
- COVID-19 vaccination | Use only Covaxin for 15-18 age cohort: Bharat Biotech
COVID-19 vaccines expected to enter clinical trials by mid April or earlier have 266 words, post on www.xinhuanet.com at March 6, 2020. This is cached page on Asean News. If you want remove this page, please contact us.